A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack - THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Ticagrelor (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms THALES
- Sponsors AstraZeneca
- 02 Mar 2018 Planned End Date changed from 5 Dec 2019 to 16 Dec 2019.
- 02 Mar 2018 Planned primary completion date changed from 5 Dec 2019 to 16 Dec 2019.
- 02 Feb 2018 Planned End Date changed from 16 Dec 2019 to 5 Dec 2019.